Sekisui Chemical To Acquire U.S. CRO XenoTech
This article was originally published in PharmAsia News
Executive Summary
TOKYO - In an effort to expand its U.S. presence in preclinical services, Sekisui Chemical Co. says it plans to acquire Kansas-based contract research organization XenoTech in an undisclosed, all-cash transaction by the end of July
You may also be interested in...
A Divesture To Kick Up Valuation For Genzyme Drives U.S. Expansion For Japanese Diagnostic Firm
TOKYO - True to its word, Genzyme sold off its diagnostics business, the second of three units the company said it would divest to generate shareholder value, but which is seen largely as a move to enhance valuation as it courts buyers. The Genzyme unit was sold to Japanese firm Sekisui Chemical, a young company that has been quick to expand its presence in the U.S
A Divesture To Kick Up Valuation For Genzyme Drives U.S. Expansion For Japanese Diagnostic Firm
TOKYO - True to its word, Genzyme sold off its diagnostics business, the second of three units the company said it would divest to generate shareholder value, but which is seen largely as a move to enhance valuation as it courts buyers. The Genzyme unit was sold to Japanese firm Sekisui Chemical, a young company that has been quick to expand its presence in the U.S
A Divesture To Kick Up Valuation For Genzyme Drives U.S. Expansion For Japanese Diagnostic Firm
Sale is the second of three units Genzyme said it would divest to generate shareholder value, but which is seen largely as a move to enhance valuation as it courts buyers.